Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Pain 10Neoplasms 9Marijuana Abuse 5Cancer Pain 5Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Signs and Symptoms 1Recurrence 1Parasomnias 1Pancreatic Neoplasms 1Neuralgia 1Nausea 1Multiple Sclerosis 1Mouth Neoplasms 1Marijuana Use 1Diabetes Mellitus 1Chronic Pain 1Cachexia 1Breast Neoplasms 1Brain Neoplasms 1Anxiety Disorders 1Anorexia 1Advanced Malignant Solid Tumor 1Advanced Cancer 11- Cancer Patients During Chemotherapy Treatment 1

Interventions

fludarabine 4Cyclophosphamide 4Specimen Handling 2Nivolumab 2Natalizumab 2Interferon beta-1b 2Fingolimod Hydrochloride 2Blood Specimen Collection 2teriflunomide 1nabiximols 1gadobutrol 1gadobenic acid 1cabozantinib 1Surveys and Questionnaires 1Respiratory Therapy 1Registries 1Platinum Compounds 1Platelet Transfusion 1Plasma Exchange 1Phlebotomy 1OM 89 1Mn-PyC3A 1Medical Marijuana 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Ipilimumab 1Interferon beta-1a 1Injections 1Gadolinium DTPA 1Fish Oils 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Sclerosis × nabiximols × Clear all
NCT02073474 2022-12-20

An Observational Post-Marketing Safety Registry of Sativex®

Jazz Pharmaceuticals

Completed
978 enrolled

Marijuana Abuse, Diabetes Mellitus, Multiple Sclerosis, Neoplasms, Neuralgia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡